Olaparib has undergone extensive clinical trials to evaluate the safety and tolerability of its use. Olaparib is a poly ADP-ribose polymerase inhibitor, derived from the chemical group of benzene-1,2-diamine derivatives, used for the treatment of certain approved cancers. As a result of its utilization, many trials have been conducted to analyze the effects of the drug on the human body.
Results from studies
In a study conducted in 2019, the safety and tolerability of Olaparib Tablet were investigated through multiple clinical trials. In this study, 568 patients were involved in a randomized, double-blind, placebo-controlled trial and administered either Olaparib or a placebo. There were two results that were collected; the incidence of adverse events and the tolerability of Olaparib when administered with other medications.
The low number of adverse events in the report
The results showed that there was an overall low number of patients who reported any serious adverse events, including those associated with drug-drug interactions while on Olaparib. This indicated that the drug was quite safe and well-tolerated by patients. Additionally, there were no deaths or major complications associated with the drug.
Biochemical changes were imitated
The researchers also noted that despite olaparib’s efficacy as a cancer treatment, it was associated with some mild side effects, such as nausea, fatigue, anemia, and headache. These side effects were more common in patients older than 65 years. Additionally, a small number of patients experienced reversible changes in liver enzymes and bilirubin levels, as well as an increase in creatinine levels, while on Olaparib. However, the study found that these risks were manageable and did not lead to any further harm.
Olaparib for recurrent glioblastoma
Olaparib has recently been approved for the treatment of recurrent glioblastoma in adults. The approval is based on the results of phase 2 clinical trial that compared Olaparib to temozolomide, the current standard treatment. The trial found that Olaparib was more effective at extending the survival of patients with recurrent glioblastoma. Specifically, the average survival of patients taking Olaparib was 23.8 months, compared to only 14.9 months for temozolomide.
Olaparib 150mg price
Olaparib 150mg is an anti-cancer pill used to treat certain types of ovarian, breast, and pancreatic cancers. It works by inhibiting the action of a naturally occurring enzyme in the body called PARP (poly ADP-ribose polymerase). While this type of drug can often be very expensive, Olaparib 150mg tablets are fairly affordable. This cost may vary depending on whether you have insurance coverage, if there are any special promotions going on, or if you opt for generic versions. All in all, Olaparib 150mg Tablet is slightly pricier than other medications but not overly expensive when considering its potential to treat cancer.
Overall, the study found that Olaparib was safe and well-tolerated by patients. The side effects reported were all relatively mild and easily managed with the necessary supervision. Furthermore, the study revealed that Olaparib did not adversely react with other medications and could be safely prescribed to patients. As such, Olaparib is an effective and safe treatment option for approved cancers.